KRAS and colorectal carcinoma: Five randomized trials were used to evaluate the prognostic value of KRAS mutations and a total of 1239 CRC patients with metastases from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included in the analysis [53].